Replies to post #95 on Proqr Therapeutics B.V. (PRQR)

[Microlytics]

Two drugs in phase II / III.

One of them (sepofarsen) already has papers published on the positive effect at 15 months. Confirmation of positive sepofarsen data will send this to $10+ near term imo.

My target by 2022 is $18/share.

[stockguard]

Has data for 3rd program adRP later this year, pivotal LCA10 data 1H 22